PATENT APPLICATION First Named Inventor or Darrell H. Carney Application Identifier Only for new nonprovisional applications under 37 C.F.R. 1.53(b)) Express Mail Label No. EL928149341 US Methods of Therapy with Thrombin Derived Peptides Title of Invention Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231 3 APPLICATION ELEMENTS ADDRESS TO: See MPEP chapter 600 concerning utility patent application contents. 6. [] Nucleotide and/or Amino Acid Sequence Submission Fee Transmittal Form (if applicable, all necessary) (Submit an original, and a duplicate for fee processing) Computer Readable Form Total Pages [24] 2. [X] Specification (preferred arrangement set forth below) Paper Copy (identical to computer copy) Descriptive title of the invention] Pages Cross References to Related Applications Statement Regarding Fed sponsored R & D Statements verifying identity of above copies c. [] Reference to sequence listing, a table, or a computer program listing appendix \$328 Background of the Invention ACCOMPANYING APPLICATION PARTS Brief Summary of the Invention 7. [] Assignment Papers (cover sheet & documents) Brief Description of the Drawings (if filed) [X] Assignee - Univ. of Texas System, Board of Regents **Detailed Description** Claim(s) Austin, Texas 78701 Abstract of the Disclosure (fi 37 C.F.R. 3.73(b) Statement 8. [] Power of Attorney [] 3. [X] Drawing(s) (35 U.S.C. 113) Total Sheets [2]];;d; [X] Fig. of the Drawings for Publication [3] [] English Translation Document (if applicable) ļ, š [] No Figure to be Published [] Copies of IDS Citations 10. [] Information Disclosure Statement (IDS)/PTO-1449 Total Pages [] 4. [] Oath or Declaration 11. [] Preliminary Amendment Newly executed (original or copy) a. [] Copy from a prior application (37 C.F.R. 1.63(d)) 12. [X] Return Receipt Postcard (for continuation/divisional with Box 17 completed) 13. [] Small Entity Statement(s) i. [] DELETION OF INVENTOR(S) Signed statement attached deleting

14a. [] Foreign Priority Claim under 35 U.S.C. §119 or 365 inventor(s) named in the prior 14b. [] Certified Copy of Priority Document(s) application, see 37 C.F.R. 1.63(d)(2) 15. [] Nonpublication Request (check parent application) and 1.33(b). 16. [X] Other Remarks Letter CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) If a CONTINUING APPLICATION, check appropriate box; supply the requisite information. 17. of prior application No.: 09/904,090 Divisional [] Continuation-in-part (CIP) [X] Continuation Group Art Unit: 1646 Prior application information: Examiner: Not Assigned The entire disclosure of the prior application is considered a part of the disclosure of the accompanying application and is hereby incorporated by reference. (Add standard Related Applications section with incorporation by reference to specification or update same) 18. CORRESPONDENCE ADDRESS Customer No. 021005 NAME HAMILTON, BROOK, SMITH & REYNOLDS, P.C. 530 Virginia Road, P.O. Box 9133 **ADDRESS** MA ZIP CODE 01742-9133 STATE CITY Concord (978) 341-0136 (978) 341-0036 FAX TELEPHONE COUNTRY USA 16,2002 Date Signature 31,240 Submitted by Typed or Printed Name Linda M. Chinn Reg. Number

01-18-05

3033.1000-008

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Attorney Docket No.

UTILITY

PATENT APPLICATION Attorney's Docket No.: 3033.1000-008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Darrell H. Carney

Continuation Application of

Application No.: 09/904,090

Filed:

July 12, 2001

For: Methods of Therapy with Thrombin Derived Peptides

Date: /-/6-02

EXPRESS MAIL LABEL NO. EL928149341 US

REMARKS

Box PATENT APPLICATION

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

The above-captioned application is a continuation of application number 09/904,090 filed on July 12, 2001 to which priority is claimed under 35 U.S.C. §120.

The related applications paragraph has been revised to include the parent application.

The parent application of this continuation application teaches that physiologically functional equivalents of thrombin derivatives encompass modifications such as amidation of the carboxyl terminus (page 10, lines 3-10). The parent application additionally teaches specific amino acid sequences of thrombin derivatives, such as SEQ ID NO.: 3 (page 2-3, lines 28 and 1, respectively).

The present application has been amended at page 3, lines 6-13, and at page 7, lines 8-11 to place the teachings of the parent application described in the previous paragraph in additional

locations in the continuation application to more readily convey this aspect of the invention to the public. Further to that end, the amino acid sequence of SEQ ID NO.: 3 has been additionally represented as a sequence with amide at the C-terminus in SEQ ID NO.: 4.

SEQ ID NO.: 4 of the parent application has now been renumbered as SEQ ID NO.: 5 in this continuation application for purposes of maintaining the continuity of the numbering of the sequences.

The subject matter of Claims 6-8 and 21-23 are first presented in this continuation application, but is fully supported in both the parent and this application. Support can be found in the specification of the parent application at least at page 10, lines 3-10 and pages 2-3, lines 28 and 1, respectively. The claims in this application have been renumbered due to the addition of the new claims, and dependencies were also suitably renumbered as necessary. In addition, an obvious typographical error, an erroneous sequence identification number, has now been corrected in Claims 5 and 20.

No new matter has been added by the amendments to the specification or by the new claims. Therefore, entry of this application as a continuation application of the parent application is respectfully requested.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Registration No. 31,240 Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133
Dated: January 16, 2002